<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00338598</url>
  </required_header>
  <id_info>
    <org_study_id>20915</org_study_id>
    <nct_id>NCT00338598</nct_id>
  </id_info>
  <brief_title>Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism</brief_title>
  <official_title>Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This placebo-controlled study is designed to evaluate the efficacy of glycine, an agonist of
      the glycine-B co-agonist site of the NMDA receptor, on alcohol consumption and craving as
      well as negative symptoms in schizophrenia.

      Glycine will decrease the rewarding action of ethanol and reduce ethanol consumption. Also,
      glycine will improve negative symptoms and cognitive deficits in schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVE: Schizophrenia affects about 1% of the general population and is a highly disabling
      disease. Additionally, the rate of alcohol dependency for patients with schizophrenia is very
      high. There are no established treatments for alcohol dependency and negative symptoms in
      schizophrenia. This study will examine whether the addition of glycine to neuroleptic
      medications will help patients with schizophrenia and alcoholism decrease their drinking as
      well as improve negative symptoms.

      RESEARCH PLAN: An abnormality of the glutamate neurotransmitter system has been hypothesized
      for both alcoholism and schizophrenia. Studies suggest that the amino acid glycine may
      improve alcohol dependency and symptoms of schizophrenia by acting on the N methyl D
      aspartate (NMDA) glutamate receptor. Glycine causes reversal of the effects of ethanol in
      animal studies and improves mood, social withdrawal and other so called &quot;negative symptoms&quot;
      of schizophrenia. Consequently, the use of glycine by patients with schizophrenia and alcohol
      dependency may potentially decrease alcohol craving and alcohol consumption and also improve
      certain symptoms of schizophrenia. The potential of glycine to improve both alcohol
      dependency and negative symptoms could represent an important step in the improvement of the
      quality of life for patients with schizophrenia.

      METHODOLOGY/FINDINGS/RESULTS: In order to test this hypothesis, we will use a double blind,
      placebo controlled study and measure the number of drinks, the degree of craving for alcohol
      and symptoms of schizophrenia among other parameters. Our principal approach to analyses of
      medication effectiveness will be the application of the linear mixed effect model. The linear
      mixed effect model permits a flexible approach for studying change in individuals through
      time as a random effect, and does not require all patients to have data at all measured
      points. Our principal model of analysis includes treatment (placebo or glycine), as between
      subject factor, and time, as within subject factor. Compliance will be also included as a
      time varying independent variable. This project continues to recruit subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Self Reported Weekly Alcohol Consumption</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of drinking days and heavy drinking days using timeline follow back</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Self Reported Weekly Alcohol Craving</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Obsessive Compulsive Drinking Scale (OCDS) is consisted by 14 items rated 0 - 4. The minimum and maximum values possibly obtained in this scale are respectively 0 and 56, this last one, meaning the most craving possible experienced. It is a short and easy to administer scale (average of 5 minutes per self-rating), built to measure severity and improvement during alcoholism treatment trials.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weekly Ratings of Negative/Positive Psychotic Symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <description>The PANSS or the Positive and Negative Syndrome Scale is a medical scale used for measuring symptom severity of patients with schizophrenia. The patient is rated from 1 to 7 on 30 different symptoms based on the interview as well as reports of family members or primary care hospital workers. Of the 30 items included in the PANSS, 7 constitute a Positive Scale, 7 a Negative Scale, and the remaining 16 a General Psychopathology Scale.The scores for these scales are arrived at by summation of ratings across component items. Therefore, the potential ranges are 7 to 49 for the Positive and Negative Scales, and 16 to 112 for the General Psychopathology Scale. A higher score indicates more severe symptoms for each scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline and End of Treatment Cognitive Functioning Measures (Hopkins)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Hopkins Verbal Learning Test Assesses short term verbal learning and memory. Subscales include immediate recall (0-36), delayed recall (0-12) , and recognition (0-12). A higher score indicates better memory performance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weekly Drug Use</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline and End of Treatment Quality of Life</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline and End of Treatment Neurophysiological Measures</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Alcoholism</condition>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Glycine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycine, 0.8 gr per kg given in two daily doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycine</intervention_name>
    <description>Glycine, 0.8 gr per kg given in two daily doses</description>
    <arm_group_label>Glycine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV diagnosis of schizophrenia or schizoaffective disorder

          -  DSM-IV diagnosis of alcohol dependence

          -  Stable treatment with typical or atypical antipsychotics

        Exclusion Criteria:

          -  Axis I diagnosis other than alcohol dependence, schizophrenia, schizoaffective
             disorder, OCD, and PTSD.

          -  current drug dependence

          -  evidence of significant hepatocellular injury evidence by abnormal SGOT or SGPT levels

          -  history of seizures

          -  diabetes and medical conditions that would alter glycine metabolism

          -  positive pregnancy test

          -  treatment with clozapine, naltrexone or disulfiram
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ismene Petrakis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2006</study_first_submitted>
  <study_first_submitted_qc>June 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2006</study_first_posted>
  <results_first_submitted>February 28, 2017</results_first_submitted>
  <results_first_submitted_qc>April 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 12, 2017</results_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glycine</keyword>
  <keyword>treatment</keyword>
  <keyword>alcohol dependence</keyword>
  <keyword>schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from the VA hospital in West Haven, CT and the Community Mental Health Center in New Haven, CT through word of mouth, advertisement and clinician referrals.</recruitment_details>
      <pre_assignment_details>Twenty men, who met DSM IV criteria for schizophrenia or schizoaffective disorder, who also met DSM IV diagnosis of alcohol dependence with at least one recent episode of heavy drinking (defined as more than 5 drinks/drinking episode) over the past 14 days participated in the study. The participants were in stable treatment for at least 2 weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Glycine</title>
          <description>Glycine, 0.8 gr per kg given in two daily doses
Glycine: Glycine, 0.8 gr per kg given in two daily doses</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo will be administered.
placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Glycine</title>
          <description>Glycine, 0.8 gr per kg given in two daily doses
Glycine: Glycine, 0.8 gr per kg given in two daily doses</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo will be administered.
placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.2" spread="4.8"/>
                    <measurement group_id="B2" value="48.6" spread="5.0"/>
                    <measurement group_id="B3" value="48.9" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Drinks per day</title>
          <units>drinks per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.9" spread="8.5"/>
                    <measurement group_id="B2" value="5.9" spread="5.0"/>
                    <measurement group_id="B3" value="7.5" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Self Reported Weekly Alcohol Consumption</title>
        <description>Percentage of drinking days and heavy drinking days using timeline follow back</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glycine</title>
            <description>Glycine, 0.8 gr per kg given in two daily doses
Glycine: Glycine, 0.8 gr per kg given in two daily doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo will be administered.
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Self Reported Weekly Alcohol Consumption</title>
          <description>Percentage of drinking days and heavy drinking days using timeline follow back</description>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% number of drinking days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4" spread="28.8"/>
                    <measurement group_id="O2" value="19.6" spread="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% number of heavy drinking days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="20.8"/>
                    <measurement group_id="O2" value="10.0" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Self Reported Weekly Alcohol Craving</title>
        <description>The Obsessive Compulsive Drinking Scale (OCDS) is consisted by 14 items rated 0 - 4. The minimum and maximum values possibly obtained in this scale are respectively 0 and 56, this last one, meaning the most craving possible experienced. It is a short and easy to administer scale (average of 5 minutes per self-rating), built to measure severity and improvement during alcoholism treatment trials.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glycine</title>
            <description>Glycine, 0.8 gr per kg given in two daily doses
Glycine: Glycine, 0.8 gr per kg given in two daily doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo will be administered.
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Self Reported Weekly Alcohol Craving</title>
          <description>The Obsessive Compulsive Drinking Scale (OCDS) is consisted by 14 items rated 0 - 4. The minimum and maximum values possibly obtained in this scale are respectively 0 and 56, this last one, meaning the most craving possible experienced. It is a short and easy to administer scale (average of 5 minutes per self-rating), built to measure severity and improvement during alcoholism treatment trials.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" spread="3.1"/>
                    <measurement group_id="O2" value="17.5" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="3.1"/>
                    <measurement group_id="O2" value="12.1" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Weekly Ratings of Negative/Positive Psychotic Symptoms</title>
        <description>The PANSS or the Positive and Negative Syndrome Scale is a medical scale used for measuring symptom severity of patients with schizophrenia. The patient is rated from 1 to 7 on 30 different symptoms based on the interview as well as reports of family members or primary care hospital workers. Of the 30 items included in the PANSS, 7 constitute a Positive Scale, 7 a Negative Scale, and the remaining 16 a General Psychopathology Scale.The scores for these scales are arrived at by summation of ratings across component items. Therefore, the potential ranges are 7 to 49 for the Positive and Negative Scales, and 16 to 112 for the General Psychopathology Scale. A higher score indicates more severe symptoms for each scale.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glycine</title>
            <description>Glycine, 0.8 gr per kg given in two daily doses
Glycine: Glycine, 0.8 gr per kg given in two daily doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo will be administered.
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Ratings of Negative/Positive Psychotic Symptoms</title>
          <description>The PANSS or the Positive and Negative Syndrome Scale is a medical scale used for measuring symptom severity of patients with schizophrenia. The patient is rated from 1 to 7 on 30 different symptoms based on the interview as well as reports of family members or primary care hospital workers. Of the 30 items included in the PANSS, 7 constitute a Positive Scale, 7 a Negative Scale, and the remaining 16 a General Psychopathology Scale.The scores for these scales are arrived at by summation of ratings across component items. Therefore, the potential ranges are 7 to 49 for the Positive and Negative Scales, and 16 to 112 for the General Psychopathology Scale. A higher score indicates more severe symptoms for each scale.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" spread="1.3"/>
                    <measurement group_id="O2" value="15.3" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" spread="1.3"/>
                    <measurement group_id="O2" value="13.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="1.5"/>
                    <measurement group_id="O2" value="12.5" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" spread="1.5"/>
                    <measurement group_id="O2" value="13.0" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline General</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" spread="2.5"/>
                    <measurement group_id="O2" value="29.4" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 General</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9" spread="2.5"/>
                    <measurement group_id="O2" value="29.8" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline and End of Treatment Cognitive Functioning Measures (Hopkins)</title>
        <description>Hopkins Verbal Learning Test Assesses short term verbal learning and memory. Subscales include immediate recall (0-36), delayed recall (0-12) , and recognition (0-12). A higher score indicates better memory performance.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glycine</title>
            <description>Glycine, 0.8 gr per kg given in two daily doses
Glycine: Glycine, 0.8 gr per kg given in two daily doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo will be administered.
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline and End of Treatment Cognitive Functioning Measures (Hopkins)</title>
          <description>Hopkins Verbal Learning Test Assesses short term verbal learning and memory. Subscales include immediate recall (0-36), delayed recall (0-12) , and recognition (0-12). A higher score indicates better memory performance.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Immediate Recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8" spread="1.7"/>
                    <measurement group_id="O2" value="19.7" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks Immediate Recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" spread="1.8"/>
                    <measurement group_id="O2" value="19.5" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Delayed Recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="0.9"/>
                    <measurement group_id="O2" value="6.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks Delayed Recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="0.9"/>
                    <measurement group_id="O2" value="6.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Recognition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="1.0"/>
                    <measurement group_id="O2" value="12.5" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks Recognition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="1.0"/>
                    <measurement group_id="O2" value="12.2" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Drug Use</title>
        <time_frame>12 weeks</time_frame>
        <population>Data was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Glycine</title>
            <description>Glycine, 0.8 gr per kg given in two daily doses
Glycine: Glycine, 0.8 gr per kg given in two daily doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo will be administered.
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Drug Use</title>
          <population>Data was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline and End of Treatment Quality of Life</title>
        <time_frame>12 weeks</time_frame>
        <population>Data was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Glycine</title>
            <description>Glycine, 0.8 gr per kg given in two daily doses
Glycine: Glycine, 0.8 gr per kg given in two daily doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo will be administered.
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline and End of Treatment Quality of Life</title>
          <population>Data was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline and End of Treatment Neurophysiological Measures</title>
        <time_frame>12 weeks</time_frame>
        <population>Data was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Glycine</title>
            <description>Glycine, 0.8 gr per kg given in two daily doses
Glycine: Glycine, 0.8 gr per kg given in two daily doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo will be administered.
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline and End of Treatment Neurophysiological Measures</title>
          <population>Data was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Glycine</title>
          <description>Glycine, 0.8 gr per kg given in two daily doses
Glycine: Glycine, 0.8 gr per kg given in two daily doses</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo will be administered.
placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ER for intoxication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>ER Visit</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Relapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>auditory hallucinations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elizabeth Ralevski Assistant Professor of Psychiatry</name_or_title>
      <organization>Yale University</organization>
      <phone>+1 203-932-5711 ext 4282</phone>
      <email>elizabeth.ralevski@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

